Key terms
About TPST
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TPST news
Apr 09
11:25am ET
Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments
Apr 04
8:12am ET
Tempest: Data from Phase 1 trial of TPST-1120 published in journal
Mar 21
2:01am ET
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
Mar 20
7:16am ET
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Mar 20
7:16am ET
Tempest Therapeutics (TPST) Receives a Buy from Scotiabank
Mar 20
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 13
4:16pm ET
Tempest Therapeutics initiated with an Outperform at Scotiabank
Mar 12
11:05am ET
Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects
Mar 12
8:29am ET
Tempest Therapeutics presents new data on TPST-1120 at SITC meeting
Feb 08
6:17am ET
Tempest Therapeutics initiated with a Buy at Jefferies
No recent press releases are available for TPST
TPST Financials
Key terms
Ad Feedback
TPST Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TPST Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range